International journal of urology : official journal of the Japanese Urological Association · 2026
Feasibility and Safety of Repeat Robot-Assisted Partial Nephrectomy for Ipsilateral Local Recurrence: A Case Series.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yukimatsu Nao, Yamasaki Takeshi, Matsue Taisuke, Yamamoto Shoma, Otoshi Taiyo, Kato Minoru, Uchida Junji
Аннотация
OBJECTIVES: To evaluate the feasibility, safety, and short-term oncological and functional outcomes of repeat robot-assisted partial nephrectomy (RAPN) for ipsilateral local recurrence of renal cell carcinoma after partial nephrectomy (PN) and describe the relevant surgical strategies.
METHODS: We retrospectively evaluated eight consecutive patients who underwent repeat RAPN between April 2019 and January 2026. Patient characteristics, perioperative outcomes, renal function, pathological findings, and adhesion severity were analyzed. Intraoperative adhesions were graded as minor or severe based on the surgeon's assessment.
RESULTS: Eleven ipsilateral recurrent tumors were analyzed in eight patients. Repeat RAPN was successfully performed in all patients without conversion to open surgery or radical nephrectomy. The median operative time, warm ischemia time, and estimated blood loss were 157 min, 15 min, and 50 mL, respectively. No major (Clavien-Dindo grade ≥ III) complications occurred. All malignant tumors were pT1a with negative surgical margins. At the median follow-up of 17.5 months, no local recurrence or distant metastasis was observed. The median eGFR values at 1 and 3 months were 57.1 and 55.7 mL/min/1.73 m2, respectively. Severe adhesions were more common among patients who did not receive anti-adhesion agents during initial surgery.
CONCLUSIONS: Repeat RAPN may be a feasible and safe salvage option for ipsilateral recurrence after PN, with acceptable early oncological and functional outcomes. Our findings suggest that anti-adhesion agent use during the initial PN may be associated with reduced adhesion-related difficulty during subsequent reoperations, although further validation is needed.
METHODS: We retrospectively evaluated eight consecutive patients who underwent repeat RAPN between April 2019 and January 2026. Patient characteristics, perioperative outcomes, renal function, pathological findings, and adhesion severity were analyzed. Intraoperative adhesions were graded as minor or severe based on the surgeon's assessment.
RESULTS: Eleven ipsilateral recurrent tumors were analyzed in eight patients. Repeat RAPN was successfully performed in all patients without conversion to open surgery or radical nephrectomy. The median operative time, warm ischemia time, and estimated blood loss were 157 min, 15 min, and 50 mL, respectively. No major (Clavien-Dindo grade ≥ III) complications occurred. All malignant tumors were pT1a with negative surgical margins. At the median follow-up of 17.5 months, no local recurrence or distant metastasis was observed. The median eGFR values at 1 and 3 months were 57.1 and 55.7 mL/min/1.73 m2, respectively. Severe adhesions were more common among patients who did not receive anti-adhesion agents during initial surgery.
CONCLUSIONS: Repeat RAPN may be a feasible and safe salvage option for ipsilateral recurrence after PN, with acceptable early oncological and functional outcomes. Our findings suggest that anti-adhesion agent use during the initial PN may be associated with reduced adhesion-related difficulty during subsequent reoperations, although further validation is needed.